Bayer ‘Outperforming’ Market As Turnaround Plan Bears Fruit
Bayer says its Consumer Health sales grew at twice the rate of the market in Q3, thanks to a number of operational changes instituted by business head Heiko Schipper back in 2018.
You may also be interested in...
Bayer Among Investors In $12M Funding For Edifice’s OTC Test For ‘Inflammatory Age’
Bayer led a $12m investment in Edifice Health, which plans to launch an OTC test kit to measure “inflammatory age” to help prevent chronic diseases. Consumer health R&D head Dave Evendon-Challis says the investment is in line with focus on deals for “big innovation jumps” in prevention.
Bayer’s Innovation Engine Shifts Up A Gear To Propel Turnaround
Bayer stepped up its Consumer Health innovation efforts in 2020 in line with its turnaround plan for the business, and now has more than 100 projects in development.
Bayer Gives Consumer Health A Star, But Plans $1.76Bn In Annual Overall Cost Reductions
Bayer notes “significant headwinds" from pandemic hitting its 2020 results likely will continue in 2021, when it t expects core earnings per share slightly below 2020 levels. While noting slumping revenues across its divisions, Bayer said an exception its consumer health business.